<DOC>
	<DOCNO>NCT01540513</DOCNO>
	<brief_summary>The purpose study evaluate diagnostic imaging technique use 124I-NM404 PET/CT human brain tumor . This goal accomplish quantify tumor uptake determine optimal PET/CT protocol , compare PET tumor uptake MRI , calculate tumor dosimetry . The long-term goal research improve diagnosis treatment malignant brain tumor use radioiodinated NM404</brief_summary>
	<brief_title>PET/CT Evaluation Primary Metastatic Brain Tumors With Novel Radioiodinated Phospholipid Ether Analogue I-NM404</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Participants contrast enhance brain MRI document evidence primary metastatic brain tumor suspect tumor recurrence therapy Tumor size least 1.5 cm great axial dimension MRI . MRI must obtain within 2 month study inclusion Adult patient 18 old Female patient must pregnant breast feed woman childbearing potential , men , must use appropriate mean contraception must maintain least 45 day injection 124INM404 Participants must attempt become pregnant time Platelet count must ≥ 160,000/µl , Hematocrit must ≥ 22 % , Leukocyte count must ≥ 3,000/µL , Creatinine must ≤ 2.5 mg/dL , ALT must ≤ 130 U/L , AST must ≤ 100 U/L , urine serum pregnancy test must negative pregnancy Patient provide informed consent Karnofsky score ≥ 60 For previously treat brain tumor , target brain therapy ( radiation drug ) must conclude ≥2 month prior injection 124INM404 Life expectancy &lt; 3 month Allergy potassium iodide ( SSKI Thyroshield ) Unwilling unable complete 3 separate PET/CT imaging session 90 minute 3 day Pregnancy breastfeed time study and/or anticipate breast feeding time 45 day injection 124INM404 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>